Back to results
US 12,740,978 B2Granted
TLR7/8 antagonists and uses thereof
AssigneeMerck Patent GmbH
InventorsLukas Shinji Okitsu, Julie DeMartino, Thomas Spangenberg
Life of this patent
Estimating the term…
Abstract
Compounds disclosed herein and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
Claims13
A method of inhibiting TLR 7 and/or 8 activity in a patient in need thereof, comprising:
- administering to said patient an effective amount of a compound selected from the group consisting of:
- and/or a pharmaceutically acceptable salt thereof, and wherein the patient in need thereof has a disorder selected from rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, systemic lupus erythematosus (SLE), lupus nephritis (LN), ankylosing spondylitis, osteoporosis, systemic sclerosis, multiple sclerosis (MS), psoriasis, type-1 diabetes, type-2 diabetes, inflammatory bowel disorder (IBD), Chrohn's Disease, ulcerative colitis, hyperimmunoqlobulinemia D and periodic fever syndrome, cryopyrin-associated periodic syndromes, Schnitzler's syndrome, systemic juvenile idiopathic arthritis, adult's onset Still's disease, qout, pseudoqout, SAPHO syndrome, Castleman's disease, sepsis, stroke, atherosclerosis, celiac disease, deficiency of IL-1 receptor agonist (DIRA), Alzheimer's disease, and Parkinson's disease.
A method for treating a TLR 7 and/or 8-mediated disorder in a patient in need thereof, comprising:
- administering to said patient a compound selected from the group consisting of:
- and/or a pharmaceutically acceptable salt thereof, and wherein the disorder is selected from rheumatoid arthritis (RA), psoriatic arthritis, osteoarthritis, systemic lupus erythematosus (SLE), lupus nephritis (LN), ankylosing spondylitis, osteoporosis, systemic sclerosis, multiple sclerosis (MS), psoriasis, type-1 diabetes, type-2 diabetes, inflammatory bowel disorder (IBD), Chrohn's Disease, ulcerative colitis, hyperimmunoglobulinemia D and periodic fever syndrome, cryopyrin-associated periodic syndromes, Schnitzler's syndrome, systemic juvenile idiopathic arthritis, adult's onset Still's disease, gout, pseudoqout, SAPHO syndrome, Castleman's disease, sepsis, stroke, atherosclerosis, celiac disease, deficiency of IL-1 receptor agonist (DIRA), Alzheimer's disease, and Parkinson's disease.
A method of treating a SARS-Co V-1 or SARS-Co V-2 infection in a human subject in need thereof, comprising:
- administering an effective amount of a compound selected from the group consisting of:
- and/or a pharmaceutically acceptable salt thereof, to said subject.
Dependencies are inferred from the claim text.